Brian O'Connell

More than $1 out of every $9 under professional management in the United States is involved in socially responsible investing.

The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008

Closer examination shows there's a strong bond between the biotech market and the unraveling credit markets.

When you start out, keep your small-cap exposure to no more than 10% of your holdings, and gradually increase.

We're seeing an uptick in biotech investing from the venture capital community, a good sign that biotech can rise even higher than the broader markets.

Investors should also scour the landscape and think creatively when investing in healthcare this year.

In the September 2006 issue I wrote about the ticklish issue of CEO pay and how shareholder groups, especially the powerful pension and other institutional groups, are growing sick and tired of CEO overpayment and underperformance.

On a recent plane ride from Phoenix to Philly, I was leafing through a copy of the San Francisco Business Journal. I was taken aback by a story on the emerging trend of biopharm exchange-traded funds (ETFs), and how much of an impact they're having on Wall Street and on investors.

There are 72 maladies for which human patients have received some benefit from adult stem cell interventions.

In the big pharma world, drugstore aisle space is every bit as important as Times Square is to New York real estate developers. And few pharma giants fill that space as well as GlaxoSmithKline.